Mineralys Therapeutics 2025 Annual Meeting Proxy Statement
Ticker: MLYS · Form: DEF 14A · Filed: Apr 9, 2025 · CIK: 1933414
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
Mineralys proxy out for May 22nd annual meeting - vote on directors & auditors.
AI Summary
Mineralys Therapeutics, Inc. is holding its 2025 Annual Meeting of Stockholders on May 22, 2025. The proxy statement details the proposals to be voted on, including the election of directors and the ratification of the appointment of its independent registered public accounting firm. The company is based in Radnor, PA, and operates in the pharmaceutical preparations industry.
Why It Matters
This filing outlines the key decisions shareholders will make regarding the company's leadership and financial oversight, impacting its future strategic direction.
Risk Assessment
Risk Level: low — This is a standard annual proxy statement detailing routine corporate governance matters.
Key Numbers
- 2025 — Annual Meeting Year (The year of the upcoming shareholder meeting.)
Key Players & Entities
- Mineralys Therapeutics, Inc. (company) — Registrant
- May 22, 2025 (date) — Annual Meeting Date
- Radnor, PA (location) — Company Headquarters
FAQ
When is the 2025 Annual Meeting of Stockholders for Mineralys Therapeutics, Inc.?
The 2025 Annual Meeting of Stockholders is scheduled for May 22, 2025.
What is the primary purpose of this DEF 14A filing?
This filing is a Proxy Statement for the Annual Meeting of Stockholders, detailing proposals for voting, including the election of directors and ratification of the independent auditor.
Where is Mineralys Therapeutics, Inc. located?
Mineralys Therapeutics, Inc. is located at 150 N. Radnor Chester Road, Suite F200, Radnor, PA 19087.
What is the SIC code for Mineralys Therapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Mineralys Therapeutics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Who is the independent registered public accounting firm for Mineralys Therapeutics, Inc.?
The proxy statement indicates that the ratification of the appointment of its independent registered public accounting firm is a proposal to be voted on by stockholders, but the specific firm's name is not provided in this excerpt.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 9, 2025 regarding Mineralys Therapeutics, Inc. (MLYS).